Montreux Equity Partners

Imperative Care, Inc. is dedicated to enhancing the speed and effectiveness of acute stroke treatment through innovative medical technologies. Founded in 2015 and based in Campbell, California, the company has developed a range of solutions aimed at addressing critical needs in stroke care. Among its offerings is the Large Distal Platform, a large diameter catheter designed to reach treatment sites for both ischemic and hemorrhagic strokes. Complementing this is the ZOOM Aspiration System, a comprehensive solution that works in conjunction with the Large Distal Platform and includes various trackable reperfusion catheters for effective clot removal. By advancing stroke treatment technologies, Imperative Care aims to improve patient outcomes and optimize recovery processes for those affected by strokes.

Tebra Technologies is a provider of digital tools and support designed to assist independent healthcare practices in navigating the complexities of the modern healthcare landscape. The company has developed a comprehensive medical technology platform that enables these practices to enhance patient acquisition, streamline care management through a fully certified electronic health record system, and improve patient engagement and billing processes. By consolidating essential functions into a single, efficient system, Tebra aims to empower healthcare professionals to optimize their operations and achieve greater success in a fragmented industry.

KEO World is a FinTech company based in Miami, Florida, that specializes in all-digital inventory financing and B2B payment solutions. The company aims to support buyers and suppliers in accelerating their business growth through innovative financial services. KEO World operates in the United States, Mexico, and throughout Latin America via its Global Trade program. Utilizing artificial intelligence and machine learning, KEO's platform analyzes banking transactional data to provide potential customers with rapid access to maximum funding. This approach enables businesses and consumers to secure instant financial support, streamlining the financing process and enhancing overall operational efficiency.

FinPay is dedicated to addressing the affordability crisis in healthcare by improving the financial experience for patients. The company offers a patient finance management platform that enhances pre-care engagement, promotes financial literacy, and advocates for cost transparency. By providing affordable payment options, FinPay aims to restore consumer trust in the American healthcare system. Additionally, the platform equips healthcare providers with analytical insights to manage financial risk effectively and optimize the collection of patient financial responsibilities. Through these initiatives, FinPay seeks to create a more accessible and transparent healthcare financial landscape.

FinPay is dedicated to addressing the affordability crisis in healthcare by improving the financial experience for patients. The company offers a patient finance management platform that enhances pre-care engagement, promotes financial literacy, and advocates for cost transparency. By providing affordable payment options, FinPay aims to restore consumer trust in the American healthcare system. Additionally, the platform equips healthcare providers with analytical insights to manage financial risk effectively and optimize the collection of patient financial responsibilities. Through these initiatives, FinPay seeks to create a more accessible and transparent healthcare financial landscape.

TigerConnect is a provider of clinical communication solutions tailored for the healthcare sector, enabling effective collaboration among doctors, nurses, patients, and care providers. Founded in 2010 and headquartered in Santa Monica, California, the company offers a platform that integrates real-time mobile messaging with a user-friendly interface, while prioritizing security and privacy. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. Its innovative products and seamless integrations with essential hospital systems enhance workflow efficiency, ultimately accelerating productivity, reducing costs, and improving patient outcomes. The company's commitment to client success is evident through its dedicated support organization, which collaborates with clients to optimize communication workflows and maximize return on investment.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Crown Laboratories, Inc. is a specialty pharmaceutical company based in Johnson City, Tennessee, founded in 2000. The company focuses on producing both prescription and non-prescription drugs, as well as cosmetic products aimed at enhancing skin health. Its product portfolio includes a range of aesthetic solutions such as SkinPen and Skinfuse, beauty products like Body Blur and Beauty Blur, and therapeutic options including Blue Lizard and PanOxyl. Additionally, Crown Laboratories offers contract manufacturing services for various formulations including solid, liquid, and semi-liquid gels and creams. The company's commitment to dermatology drives its mission to improve the quality of life for consumers through effective skincare solutions.

GC Aesthetics is a company focused on female aesthetics, specializing in the development, manufacturing, and commercialization of silicone breast implants. The company offers a variety of surgical implants and tissue expanders that provide surgeons with options for breast augmentation, aesthetic enhancement, and reconstructive surgery. Additionally, GC Aesthetics develops silicone products for scar management, including a product line designed to improve the appearance of scars. The company also supports patients and surgeons through educational resources and a patient generator program known as Business Boost. With its headquarters in Dublin, Ireland, and manufacturing facilities located in Scotland, England, and France, GC Aesthetics serves both local and international markets, emphasizing innovation and quality to enhance the body transformation journey for women. Established in 2015, the company leverages over 30 years of industry experience to empower individuals and promote confidence in their aesthetic choices.

Sonoma Pharmaceuticals, Inc. is a global healthcare company that develops and produces stabilized hypochlorous acid (HOCl) products for diverse applications, including wound care, dermatology, animal health, eye care, and oral care. Based in Woodstock, Georgia, and incorporated in 1999, the company offers over 100 commercially available products worldwide. Its key offerings include Epicyn, an antimicrobial facial cleanser; Levicyn, a prescription product for managing dermatoses; Celacyn gel for scar management; and SebuDerm for seborrhea relief. Additionally, Sonoma provides Acuicyn for eye care, Microcyn for expedited wound healing, and various products targeting animal health, such as MicrocynAH and MicrocynVS. The company's focus on addressing unmet medical needs in chronic skin conditions significantly contributes to enhancing patient care while aiming to reduce overall healthcare costs. Sonoma Pharmaceuticals was previously known as Oculus Innovative Sciences, Inc. and rebranded in December 2016.

Colorescience, Inc. is a skincare brand based in Carlsbad, California, specializing in mineral-based cosmetics and sunscreen products. Founded in 2000, the company offers a range of items, including treatment products, UV protectors, primers, foundations, and enhancers, designed to address various skin concerns such as pigmentation, redness, dark circles, and signs of aging. Colorescience emphasizes high-quality, dermatologist-recommended formulations that incorporate minerals, antioxidants, and botanicals to promote healthy skin and protect against sun damage. The brand markets its products through a network of licensed physicians, luxury spas, retailers, and online platforms, aiming to stand out in the aesthetic makeup segment by providing effective and easy-to-use solutions for diverse skin types.

GC Aesthetics is a company focused on female aesthetics, specializing in the development, manufacturing, and commercialization of silicone breast implants. The company offers a variety of surgical implants and tissue expanders that provide surgeons with options for breast augmentation, aesthetic enhancement, and reconstructive surgery. Additionally, GC Aesthetics develops silicone products for scar management, including a product line designed to improve the appearance of scars. The company also supports patients and surgeons through educational resources and a patient generator program known as Business Boost. With its headquarters in Dublin, Ireland, and manufacturing facilities located in Scotland, England, and France, GC Aesthetics serves both local and international markets, emphasizing innovation and quality to enhance the body transformation journey for women. Established in 2015, the company leverages over 30 years of industry experience to empower individuals and promote confidence in their aesthetic choices.

SI-BONE, Inc. is a medical device company based in Santa Clara, California, specializing in the development and commercialization of implantable devices for the surgical treatment of the sacropelvic anatomy. Founded in 2008, the company offers the iFuse implant system, a minimally invasive solution designed to fuse the sacroiliac joint to alleviate lower back pain caused by sacroiliac joint dysfunction. The iFuse implant utilizes a patented titanium fixation system and a cannulated delivery method, making the procedure quicker and simpler compared to traditional open fusion techniques. In addition to the iFuse, SI-BONE's product portfolio includes other patented implants and instruments, such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which are used in various applications, including adult spinal deformity, degeneration, and pelvic trauma.

Kareo is the leading cloud-based, clinical and business management platform designed specifically for the independent practice. Kareo’s integrated modules work together as part of a seamless platform, so independent practices have helpful tools to tackle their toughest administrative challenges. These tools include electronic health records, practice management, billing, marketing and patient engagement software. Plus, proven, integrated third-party applications and services in Kareo Marketplace to make delivering care even easier. Today we help over 50,000 providers in all 50 states run more efficient and profitable practices, while delivering outstanding patient care. Kareo has received extensive industry recognition, including being awarded the 2018 United States Ambulatory EHR Enabling Technology Leadership Award from Frost and Sullivan, Deloitte Technology Fast 500, Inc. 5000 and Black Book’s #1 Integrated EHR, Practice Management and Medical Billing Vendor. With offices across the country, our mission is to help independent practices succeed in an ever-changing healthcare market.

SI-BONE, Inc. is a medical device company based in Santa Clara, California, specializing in the development and commercialization of implantable devices for the surgical treatment of the sacropelvic anatomy. Founded in 2008, the company offers the iFuse implant system, a minimally invasive solution designed to fuse the sacroiliac joint to alleviate lower back pain caused by sacroiliac joint dysfunction. The iFuse implant utilizes a patented titanium fixation system and a cannulated delivery method, making the procedure quicker and simpler compared to traditional open fusion techniques. In addition to the iFuse, SI-BONE's product portfolio includes other patented implants and instruments, such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which are used in various applications, including adult spinal deformity, degeneration, and pelvic trauma.

Pure Life Renal, LLC is a dialysis service provider based in Hollywood, Florida, established in 2013. The company specializes in delivering comprehensive kidney care, including in-center hemodialysis, home hemodialysis, and peritoneal dialysis, catering primarily to patients with end-stage renal disease. Pure Life Renal focuses on collaboration with nephrologists, offering them the opportunity to partner in clinic development or acquisition, which enhances their ability to manage patient care effectively. The company provides essential business and operational management tools, allowing physicians to concentrate on delivering quality care within a well-structured environment.

SI-BONE, Inc. is a medical device company based in Santa Clara, California, specializing in the development and commercialization of implantable devices for the surgical treatment of the sacropelvic anatomy. Founded in 2008, the company offers the iFuse implant system, a minimally invasive solution designed to fuse the sacroiliac joint to alleviate lower back pain caused by sacroiliac joint dysfunction. The iFuse implant utilizes a patented titanium fixation system and a cannulated delivery method, making the procedure quicker and simpler compared to traditional open fusion techniques. In addition to the iFuse, SI-BONE's product portfolio includes other patented implants and instruments, such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which are used in various applications, including adult spinal deformity, degeneration, and pelvic trauma.

EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.

GC Aesthetics is a company focused on female aesthetics, specializing in the development, manufacturing, and commercialization of silicone breast implants. The company offers a variety of surgical implants and tissue expanders that provide surgeons with options for breast augmentation, aesthetic enhancement, and reconstructive surgery. Additionally, GC Aesthetics develops silicone products for scar management, including a product line designed to improve the appearance of scars. The company also supports patients and surgeons through educational resources and a patient generator program known as Business Boost. With its headquarters in Dublin, Ireland, and manufacturing facilities located in Scotland, England, and France, GC Aesthetics serves both local and international markets, emphasizing innovation and quality to enhance the body transformation journey for women. Established in 2015, the company leverages over 30 years of industry experience to empower individuals and promote confidence in their aesthetic choices.

Mindbody is a wellness experience platform that connects users to fitness, beauty, and integrative health services. Fitness studios, salons, spas, and integrative health centers—use Mindbody's integrated software and payments platform to run, market, and grow their businesses. Consumers use Mindbody to find, engage, and transact with wellness providers in their local communities and around the world. Mindbody helps people lead healthier, happier lives by connecting the world to wellness. It was founded in 2001 and headquartered in San Luis Obispo, California.

Colorescience, Inc. is a skincare brand based in Carlsbad, California, specializing in mineral-based cosmetics and sunscreen products. Founded in 2000, the company offers a range of items, including treatment products, UV protectors, primers, foundations, and enhancers, designed to address various skin concerns such as pigmentation, redness, dark circles, and signs of aging. Colorescience emphasizes high-quality, dermatologist-recommended formulations that incorporate minerals, antioxidants, and botanicals to promote healthy skin and protect against sun damage. The brand markets its products through a network of licensed physicians, luxury spas, retailers, and online platforms, aiming to stand out in the aesthetic makeup segment by providing effective and easy-to-use solutions for diverse skin types.

Glaukos Corporation is an ophthalmic medical technology company dedicated to developing innovative products and procedures aimed at transforming the treatment of glaucoma, a major cause of blindness worldwide. The company has pioneered Micro-Invasive Glaucoma Surgery (MIGS) to enhance traditional glaucoma management approaches. Its flagship product, the iStent, was introduced in the United States in 2012 and is designed as a micro-bypass stent that can be inserted during cataract surgery to lower intraocular pressure in adults with mild-to-moderate open-angle glaucoma. Glaukos is also advancing its product pipeline with the iStent SA, a two-stent system that utilizes a unique auto-injection inserter for standalone procedures. Founded in 1998 and headquartered in San Clemente, California, Glaukos aims to build a comprehensive portfolio of injectable micro-scale therapies to address various glaucoma disease states and progression.

EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.

EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Pivot Medical is a privately held medical device company that specializes in developing and marketing innovative technologies for the orthopedic market. The company focuses on creating minimally invasive hip-replacement devices and advancing arthroscopic surgery techniques. Its products are designed to enhance surgical access and reduce recovery times for patients. Pivot Medical aims to address the needs of active individuals seeking effective treatment options while minimizing the impact of surgery on their daily lives.

SI-BONE, Inc. is a medical device company based in Santa Clara, California, specializing in the development and commercialization of implantable devices for the surgical treatment of the sacropelvic anatomy. Founded in 2008, the company offers the iFuse implant system, a minimally invasive solution designed to fuse the sacroiliac joint to alleviate lower back pain caused by sacroiliac joint dysfunction. The iFuse implant utilizes a patented titanium fixation system and a cannulated delivery method, making the procedure quicker and simpler compared to traditional open fusion techniques. In addition to the iFuse, SI-BONE's product portfolio includes other patented implants and instruments, such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which are used in various applications, including adult spinal deformity, degeneration, and pelvic trauma.

Glaukos Corporation is an ophthalmic medical technology company dedicated to developing innovative products and procedures aimed at transforming the treatment of glaucoma, a major cause of blindness worldwide. The company has pioneered Micro-Invasive Glaucoma Surgery (MIGS) to enhance traditional glaucoma management approaches. Its flagship product, the iStent, was introduced in the United States in 2012 and is designed as a micro-bypass stent that can be inserted during cataract surgery to lower intraocular pressure in adults with mild-to-moderate open-angle glaucoma. Glaukos is also advancing its product pipeline with the iStent SA, a two-stent system that utilizes a unique auto-injection inserter for standalone procedures. Founded in 1998 and headquartered in San Clemente, California, Glaukos aims to build a comprehensive portfolio of injectable micro-scale therapies to address various glaucoma disease states and progression.

GC Aesthetics is a company focused on female aesthetics, specializing in the development, manufacturing, and commercialization of silicone breast implants. The company offers a variety of surgical implants and tissue expanders that provide surgeons with options for breast augmentation, aesthetic enhancement, and reconstructive surgery. Additionally, GC Aesthetics develops silicone products for scar management, including a product line designed to improve the appearance of scars. The company also supports patients and surgeons through educational resources and a patient generator program known as Business Boost. With its headquarters in Dublin, Ireland, and manufacturing facilities located in Scotland, England, and France, GC Aesthetics serves both local and international markets, emphasizing innovation and quality to enhance the body transformation journey for women. Established in 2015, the company leverages over 30 years of industry experience to empower individuals and promote confidence in their aesthetic choices.

Tobira Therapeutics, Inc. is a biotechnology company based in Princeton, New Jersey, focused on the research, development, and commercialization of antiviral compounds aimed at addressing life-threatening infectious diseases. Founded in 2006, the company specializes in developing TBR-652 and TBR-220 antagonists specifically for the treatment of HIV/AIDS and hepatitis, along with other related infectious conditions. Through its innovative approach, Tobira Therapeutics seeks to provide effective therapies for patients suffering from these serious health challenges.

Avantis Medical Systems, Inc. is a medical device company based in Sunnyvale, California, focused on developing catheter-based endoscopic devices aimed at detecting and treating cancers and other abnormalities in the gastrointestinal (GI) tract. The company leverages advanced technologies, including micro-chips and reinforced catheters, to create innovative solutions that enhance healthcare visualization and improve patient outcomes. With a team possessing extensive experience in the medical device industry, Avantis is dedicated to providing safe, cost-effective services that facilitate faster recovery for patients.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

moksha8 Pharmaceuticals, Inc. is a pharmaceutical company that operates in Brazil and Mexico, focusing on the licensing, marketing, and distribution of therapeutics. The company specializes in treatments for various medical fields, including central nervous system disorders, oncology, cardiology, rheumatology, endocrinology, and respiratory conditions. Established in 2006 and based in Berwyn, Pennsylvania, moksha8 has formed strategic alliances with several prominent organizations, including Biopas Laboratories, Roche, Pfizer, BioCryst, and Watson. These partnerships enhance its ability to deliver innovative healthcare solutions in the Latin American market.

Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing proprietary branded prescription therapeutics aimed at addressing significant medical conditions with unmet needs. The company is primarily engaged in in-licensing and marketing late-stage product candidates within the central nervous system therapeutic area. Somaxon is known for promoting Silenor®, the first and only nonscheduled prescription medication approved for the treatment of sleep maintenance insomnia, which is currently available in the United States. In addition to sleep disorders, Somaxon has also developed products for the treatment of other conditions, including middle ear infections, head lice, and cough and cold.

NovoStent Corporation, a medical device company that has developed a novel "anchored" helical stent technology to provide a wide range of vascular therapies.

Mako Surgical is a medical device company based in Florida, specializing in advanced robotic arm solutions and orthopedic implants for minimally invasive procedures, particularly in knee and hip surgeries. The company’s flagship offering, MAKOplasty, is a restorative surgical solution designed to assist orthopedic surgeons in treating early to mid-stage osteoarthritic conditions in patients. Mako Surgical's robotic arm interactive orthopedic system (RIO) features a tactile robotic arm and an integrated bone cutting instrument, providing pre-operative and intra-operative guidance to enhance surgical precision. This technology facilitates tissue-sparing bone removal and accurate implant insertion and alignment, ultimately improving patient outcomes. Founded in 2004, Mako Surgical has gained recognition in the medical technology field, having been named the fastest growing technology company by Deloitte and receiving multiple awards for customer excellence and innovation.

Glaukos Corporation is an ophthalmic medical technology company dedicated to developing innovative products and procedures aimed at transforming the treatment of glaucoma, a major cause of blindness worldwide. The company has pioneered Micro-Invasive Glaucoma Surgery (MIGS) to enhance traditional glaucoma management approaches. Its flagship product, the iStent, was introduced in the United States in 2012 and is designed as a micro-bypass stent that can be inserted during cataract surgery to lower intraocular pressure in adults with mild-to-moderate open-angle glaucoma. Glaukos is also advancing its product pipeline with the iStent SA, a two-stent system that utilizes a unique auto-injection inserter for standalone procedures. Founded in 1998 and headquartered in San Clemente, California, Glaukos aims to build a comprehensive portfolio of injectable micro-scale therapies to address various glaucoma disease states and progression.

Pivot Medical is a privately held medical device company that specializes in developing and marketing innovative technologies for the orthopedic market. The company focuses on creating minimally invasive hip-replacement devices and advancing arthroscopic surgery techniques. Its products are designed to enhance surgical access and reduce recovery times for patients. Pivot Medical aims to address the needs of active individuals seeking effective treatment options while minimizing the impact of surgery on their daily lives.

Novalar Pharmaceuticals, Inc., a pharmaceutical company, develops oral pharmaceutical products. It focuses on dental products. The company’s OraVerse product (phentolamine mesylate) reverses the effects of local anesthetic with a vasoconstrictor and accelerates the return of normal sensation and function. Novalar Pharmaceuticals, Inc. was founded in 2000 and is based in San Diego, California. As of March 22, 2011, Novalar Pharmaceuticals, Inc. operates as a subsidiary of Septodont Limited.

Sequel Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes novel and clinical-stage drug candidates for patients with cardiovascular disease. The company was founded in 2007 and is based in San Diego, California.

Novalar Pharmaceuticals, Inc., a pharmaceutical company, develops oral pharmaceutical products. It focuses on dental products. The company’s OraVerse product (phentolamine mesylate) reverses the effects of local anesthetic with a vasoconstrictor and accelerates the return of normal sensation and function. Novalar Pharmaceuticals, Inc. was founded in 2000 and is based in San Diego, California. As of March 22, 2011, Novalar Pharmaceuticals, Inc. operates as a subsidiary of Septodont Limited.

KFx Medical specializes in developing and manufacturing innovative soft tissue fixation implants tailored for orthopedic sports medicine. The company offers a range of products designed for tissue fixation, which can be directly placed into bones with or without sutures. These implants are applicable in various orthopedic surgical procedures, allowing surgeons to effectively reattach tissue in regions such as the shoulder, knee, foot, and ankle. KFx Medical collaborates closely with leading orthopedic surgeons to create advanced technologies and reliable surgical implants, ultimately aiming to improve surgical outcomes for patients.

Tobira Therapeutics, Inc. is a biotechnology company based in Princeton, New Jersey, focused on the research, development, and commercialization of antiviral compounds aimed at addressing life-threatening infectious diseases. Founded in 2006, the company specializes in developing TBR-652 and TBR-220 antagonists specifically for the treatment of HIV/AIDS and hepatitis, along with other related infectious conditions. Through its innovative approach, Tobira Therapeutics seeks to provide effective therapies for patients suffering from these serious health challenges.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

NovaCardia is a pharmaceutical company specializing in the development of drugs for cardiovascular diseases. With a strong focus on acute cardiac care, the company is dedicated to enhancing patient outcomes through the creation and commercialization of innovative small molecule therapies. Among its key projects is an oral formulation of KW-3902, aimed at treating chronic congestive heart failure. NovaCardia's expertise in cardiovascular drug development positions it to make significant contributions to the field and improve the quality of care for patients suffering from these conditions.

Transcept Pharmaceuticals, Inc. is engaged in the development of proprietary products aimed at addressing therapeutic needs in neuroscience. The company utilizes a unique delivery system that enhances drug penetration and accelerates their onset of action. Transcept is focused on creating rapid-acting formulations of several established pharmaceuticals, seeking to improve patient outcomes in various neurological conditions. The company has attracted investment from notable firms, including Montreaux Equity Partners, Peninsula Equity Partners, Vivo Ventures, New Leaf Venture Partners, Interwest Partners, and New Enterprise Associates, supporting its ongoing research and development efforts.

Pivot Medical is a privately held medical device company that specializes in developing and marketing innovative technologies for the orthopedic market. The company focuses on creating minimally invasive hip-replacement devices and advancing arthroscopic surgery techniques. Its products are designed to enhance surgical access and reduce recovery times for patients. Pivot Medical aims to address the needs of active individuals seeking effective treatment options while minimizing the impact of surgery on their daily lives.

Avantis Medical Systems, Inc. is a medical device company based in Sunnyvale, California, focused on developing catheter-based endoscopic devices aimed at detecting and treating cancers and other abnormalities in the gastrointestinal (GI) tract. The company leverages advanced technologies, including micro-chips and reinforced catheters, to create innovative solutions that enhance healthcare visualization and improve patient outcomes. With a team possessing extensive experience in the medical device industry, Avantis is dedicated to providing safe, cost-effective services that facilitate faster recovery for patients.

NovaCardia is a pharmaceutical company specializing in the development of drugs for cardiovascular diseases. With a strong focus on acute cardiac care, the company is dedicated to enhancing patient outcomes through the creation and commercialization of innovative small molecule therapies. Among its key projects is an oral formulation of KW-3902, aimed at treating chronic congestive heart failure. NovaCardia's expertise in cardiovascular drug development positions it to make significant contributions to the field and improve the quality of care for patients suffering from these conditions.

SkinMedica is a company dedicated to developing, acquiring, and commercializing products aimed at improving skin appearance. It specializes in both prescription and non-prescription skincare solutions marketed primarily to physicians and medical spas. The company's notable offerings include the TNS Essential Serum® and TNS Recovery Complex®, which are designed to enhance skin quality, reduce signs of aging, and deliver various skincare benefits. SkinMedica's prescription product, VANIQA® Cream, is the only FDA-approved treatment for the reduction of unwanted facial hair in women. Additionally, SkinMedica's portfolio includes a range of aesthetic skincare products, moisturizers, sun protection, and specialized treatments for conditions such as acne and sensitive skin. The company also features Colorescience Pro, a line of dermatologist-recommended cosmetics that address specific skin concerns while providing sun protection.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

Aryx Therapeutics is a biopharmaceutical company dedicated to developing innovative drug candidates that address safety concerns associated with established oral therapies for chronic diseases. Leveraging its expertise in retrometabolic drug design, Aryx aims to create safer alternatives to commercially successful medications. The company is committed to improving patient outcomes through its internally developed products, which are designed to mitigate known safety issues and enhance the effectiveness of existing treatments.

Asthmatx, Inc. is a medical device company based in Mountain View, California, that specializes in the development and commercialization of therapeutic treatments for asthma. Founded in 2003, the company has created a technology that delivers controlled thermal energy to the airways of adult patients, aimed at reducing the mass of airway smooth muscle through a procedure known as Bronchial Thermoplasty. Asthmatx offers the Alair System, an interventional medical device designed for bronchoscopic treatment of patients suffering from moderate to severe asthma. As of October 2010, Asthmatx operates as a wholly-owned subsidiary of Boston Scientific.

NeurogesX, Inc. is a specialty pharmaceutical company based in San Mateo, California, established in 1998 and originally named Advanced Analgesics, Inc. The company is dedicated to developing and commercializing non-opioid therapies for pain management, specifically targeting chronic peripheral neuropathic pain conditions such as postherpetic neuralgia, painful HIV-distal sensory polyneuropathy, and painful diabetic neuropathy. Its lead product is Qutenza, an 8% capsaicin dermal patch designed to manage pain through a novel delivery system. In addition to Qutenza, NeurogesX is also working on NGX-1998, a non-patch liquid formulation of synthetic capsaicin, and an opioid analgesic aimed at treating other chronic pain conditions, including cancer pain.

KFx Medical specializes in developing and manufacturing innovative soft tissue fixation implants tailored for orthopedic sports medicine. The company offers a range of products designed for tissue fixation, which can be directly placed into bones with or without sutures. These implants are applicable in various orthopedic surgical procedures, allowing surgeons to effectively reattach tissue in regions such as the shoulder, knee, foot, and ankle. KFx Medical collaborates closely with leading orthopedic surgeons to create advanced technologies and reliable surgical implants, ultimately aiming to improve surgical outcomes for patients.

Cerexa is a biopharmaceutical company dedicated to developing innovative anti-infective therapies aimed at treating serious and life-threatening infections. The company's primary focus is on addressing antibiotic-resistant infections, and it offers a portfolio that includes Ceftaroline, an injectable cephalosporin effective against bacterial infections caused by both gram-positive and gram-negative pathogens.

Verus Pharmaceuticals is a pediatric-oriented company that identifies, develops, and delivers solutions to address the unmet medical needs of children and those who care for them. It offers treatment of asthma, allergies, and related diseases and conditions. The company also offers Twinject, an epinephrine auto-injector for anaphylaxis. Verus Pharmaceuticals is based in San Diego, California.

Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing proprietary branded prescription therapeutics aimed at addressing significant medical conditions with unmet needs. The company is primarily engaged in in-licensing and marketing late-stage product candidates within the central nervous system therapeutic area. Somaxon is known for promoting Silenor®, the first and only nonscheduled prescription medication approved for the treatment of sleep maintenance insomnia, which is currently available in the United States. In addition to sleep disorders, Somaxon has also developed products for the treatment of other conditions, including middle ear infections, head lice, and cough and cold.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

NovaCardia is a pharmaceutical company specializing in the development of drugs for cardiovascular diseases. With a strong focus on acute cardiac care, the company is dedicated to enhancing patient outcomes through the creation and commercialization of innovative small molecule therapies. Among its key projects is an oral formulation of KW-3902, aimed at treating chronic congestive heart failure. NovaCardia's expertise in cardiovascular drug development positions it to make significant contributions to the field and improve the quality of care for patients suffering from these conditions.

SkinMedica is a company dedicated to developing, acquiring, and commercializing products aimed at improving skin appearance. It specializes in both prescription and non-prescription skincare solutions marketed primarily to physicians and medical spas. The company's notable offerings include the TNS Essential Serum® and TNS Recovery Complex®, which are designed to enhance skin quality, reduce signs of aging, and deliver various skincare benefits. SkinMedica's prescription product, VANIQA® Cream, is the only FDA-approved treatment for the reduction of unwanted facial hair in women. Additionally, SkinMedica's portfolio includes a range of aesthetic skincare products, moisturizers, sun protection, and specialized treatments for conditions such as acne and sensitive skin. The company also features Colorescience Pro, a line of dermatologist-recommended cosmetics that address specific skin concerns while providing sun protection.

Orexigen Therapeutics, Inc. is a biopharmaceutical company dedicated to developing pharmaceutical products aimed at treating obesity. Founded in 2002 and based in La Jolla, California, the company has advanced its lead product candidates, including Contrave, which has completed Phase III clinical trials, and Empatic, which has completed Phase II clinical trials. Contrave is a combination of bupropion, an antidepressant and smoking cessation aid, and naltrexone, used for treating alcohol and opioid addiction. Empatic combines bupropion with zonisamide, a medication for epilepsy, in a sustained release formulation. Orexigen's focus includes exploring older drugs for synergistic effects in addressing obesity and related conditions.

Novalar Pharmaceuticals, Inc., a pharmaceutical company, develops oral pharmaceutical products. It focuses on dental products. The company’s OraVerse product (phentolamine mesylate) reverses the effects of local anesthetic with a vasoconstrictor and accelerates the return of normal sensation and function. Novalar Pharmaceuticals, Inc. was founded in 2000 and is based in San Diego, California. As of March 22, 2011, Novalar Pharmaceuticals, Inc. operates as a subsidiary of Septodont Limited.

Avera Pharmaceuticals is a specialty pharmaceutical company that acquires, develops, and commercializes pharmaceutical compounds. The company develops gantacurium, a neuromuscular blocking agent for rapid and routine endotracheal intubation and skeletal muscle relaxation during surgery; AV810 for the treatment of overactive bladder and irritable bowel syndrome; and AV965 to treat cognitive impairment associated with schizophrenia and Alzheimer’s dementia. The company was founded in 2002 and is headquartered in San Diego, California.

SkinMedica is a company dedicated to developing, acquiring, and commercializing products aimed at improving skin appearance. It specializes in both prescription and non-prescription skincare solutions marketed primarily to physicians and medical spas. The company's notable offerings include the TNS Essential Serum® and TNS Recovery Complex®, which are designed to enhance skin quality, reduce signs of aging, and deliver various skincare benefits. SkinMedica's prescription product, VANIQA® Cream, is the only FDA-approved treatment for the reduction of unwanted facial hair in women. Additionally, SkinMedica's portfolio includes a range of aesthetic skincare products, moisturizers, sun protection, and specialized treatments for conditions such as acne and sensitive skin. The company also features Colorescience Pro, a line of dermatologist-recommended cosmetics that address specific skin concerns while providing sun protection.

Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing proprietary branded prescription therapeutics aimed at addressing significant medical conditions with unmet needs. The company is primarily engaged in in-licensing and marketing late-stage product candidates within the central nervous system therapeutic area. Somaxon is known for promoting Silenor®, the first and only nonscheduled prescription medication approved for the treatment of sleep maintenance insomnia, which is currently available in the United States. In addition to sleep disorders, Somaxon has also developed products for the treatment of other conditions, including middle ear infections, head lice, and cough and cold.

Aryx Therapeutics is a biopharmaceutical company dedicated to developing innovative drug candidates that address safety concerns associated with established oral therapies for chronic diseases. Leveraging its expertise in retrometabolic drug design, Aryx aims to create safer alternatives to commercially successful medications. The company is committed to improving patient outcomes through its internally developed products, which are designed to mitigate known safety issues and enhance the effectiveness of existing treatments.

NeurogesX, Inc. is a specialty pharmaceutical company based in San Mateo, California, established in 1998 and originally named Advanced Analgesics, Inc. The company is dedicated to developing and commercializing non-opioid therapies for pain management, specifically targeting chronic peripheral neuropathic pain conditions such as postherpetic neuralgia, painful HIV-distal sensory polyneuropathy, and painful diabetic neuropathy. Its lead product is Qutenza, an 8% capsaicin dermal patch designed to manage pain through a novel delivery system. In addition to Qutenza, NeurogesX is also working on NGX-1998, a non-patch liquid formulation of synthetic capsaicin, and an opioid analgesic aimed at treating other chronic pain conditions, including cancer pain.

Peninsula Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the licensing, development, and commercialization of anti-infective therapies aimed at treating life-threatening infections in North America and Europe. The company's primary focus is on its lead product candidate, doripenem, a broad-spectrum antibiotic classified as a carbapenem. Currently, Peninsula is conducting six Phase III clinical trials for doripenem, which has also received Fast Track designation from the U.S. Food and Drug Administration for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia. The company was acquired by Johnson & Johnson, a global leader in healthcare products and services. As a privately held biopharmaceutical entity, Peninsula Pharmaceuticals concentrates on advancing antibiotics to address critical infection-related health challenges.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Marketwired is a social communications company that specializes in press release distribution and communication workflow services. Founded in 1983 and headquartered in Toronto, Ontario, it offers a comprehensive suite of solutions that includes social media monitoring, analytics, and a marketing communications platform for content creation, optimization, distribution, and measurement. Marketwired serves a diverse clientele, ranging from Fortune 500 companies to start-ups, and plays a vital role in influencing public discourse across newsrooms, corporate environments, and social networks. Its services are designed to help clients manage public relations and investor relations effectively, facilitating engagement and impacting consumer behavior.

Peninsula Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the licensing, development, and commercialization of anti-infective therapies aimed at treating life-threatening infections in North America and Europe. The company's primary focus is on its lead product candidate, doripenem, a broad-spectrum antibiotic classified as a carbapenem. Currently, Peninsula is conducting six Phase III clinical trials for doripenem, which has also received Fast Track designation from the U.S. Food and Drug Administration for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia. The company was acquired by Johnson & Johnson, a global leader in healthcare products and services. As a privately held biopharmaceutical entity, Peninsula Pharmaceuticals concentrates on advancing antibiotics to address critical infection-related health challenges.

PartnerGate specializes in domain management, development and programming.

NeurogesX, Inc. is a specialty pharmaceutical company based in San Mateo, California, established in 1998 and originally named Advanced Analgesics, Inc. The company is dedicated to developing and commercializing non-opioid therapies for pain management, specifically targeting chronic peripheral neuropathic pain conditions such as postherpetic neuralgia, painful HIV-distal sensory polyneuropathy, and painful diabetic neuropathy. Its lead product is Qutenza, an 8% capsaicin dermal patch designed to manage pain through a novel delivery system. In addition to Qutenza, NeurogesX is also working on NGX-1998, a non-patch liquid formulation of synthetic capsaicin, and an opioid analgesic aimed at treating other chronic pain conditions, including cancer pain.

Marketwired is a social communications company that specializes in press release distribution and communication workflow services. Founded in 1983 and headquartered in Toronto, Ontario, it offers a comprehensive suite of solutions that includes social media monitoring, analytics, and a marketing communications platform for content creation, optimization, distribution, and measurement. Marketwired serves a diverse clientele, ranging from Fortune 500 companies to start-ups, and plays a vital role in influencing public discourse across newsrooms, corporate environments, and social networks. Its services are designed to help clients manage public relations and investor relations effectively, facilitating engagement and impacting consumer behavior.

NeurogesX, Inc. is a specialty pharmaceutical company based in San Mateo, California, established in 1998 and originally named Advanced Analgesics, Inc. The company is dedicated to developing and commercializing non-opioid therapies for pain management, specifically targeting chronic peripheral neuropathic pain conditions such as postherpetic neuralgia, painful HIV-distal sensory polyneuropathy, and painful diabetic neuropathy. Its lead product is Qutenza, an 8% capsaicin dermal patch designed to manage pain through a novel delivery system. In addition to Qutenza, NeurogesX is also working on NGX-1998, a non-patch liquid formulation of synthetic capsaicin, and an opioid analgesic aimed at treating other chronic pain conditions, including cancer pain.

StorageWay, Inc. provides storage utility services. Its services are offered by Internet infrastructure providers in Santa Clara, New York, Atlanta, Chicago, Washington DC, and Dallas; and Toronto, Canada.

Internet Generation Storage

PartnerGate specializes in domain management, development and programming.

Cephren – the master builder of the great pyramids. He changed the way the world was built. With the help of their customers, they will too! Welcome to Cephren, the premier business-to-business online workplace for the global construction industry. Cephren unites all participants in the industry with the first end-to-end, Web-based framework of e-commerce and collaboration services. Whether you're an owner or developer, architect or engineer, general contractor or subcontractor, distributor or manufacturer, Cephren's online workplace addresses your needs throughout the design-to-build process, enabling you to do business smarter, faster and more cost effectively.

Marketwired is a social communications company that specializes in press release distribution and communication workflow services. Founded in 1983 and headquartered in Toronto, Ontario, it offers a comprehensive suite of solutions that includes social media monitoring, analytics, and a marketing communications platform for content creation, optimization, distribution, and measurement. Marketwired serves a diverse clientele, ranging from Fortune 500 companies to start-ups, and plays a vital role in influencing public discourse across newsrooms, corporate environments, and social networks. Its services are designed to help clients manage public relations and investor relations effectively, facilitating engagement and impacting consumer behavior.